Email
Print
Nucleic Acid Aptamers Market Size is estimated to reach $412.3 million by 2027 and it is poised to grow at a CAGR of 17.4% over the forecast period of 2022-2027. Aptamers are small single-stranded oligonucleotides (DNAs or
RNAs) with comparatively low molecular weight, ranging from 5-40 kDa. Nucleic acid
aptamer groups have more flexibility and minor complexity and immunogenicity
allowing them to attach to interior non-accessible epitopes that cannot be
easily targeted by antibodies. Aptamer sciences have been applied in
various life sciences fields as new drugs, nanoparticle agents for diagnostic and bio-imaging, drug-delivery agents, analytical
reagents, food, and hazard detection applications. The nucleic acid aptamers
market in the U.S. is majorly driven by the aptamer companies in the U.S. who
are constantly evolving the sphere of research to curate products and services
which serve a wider purpose, while various clinical trials are being performed to expand the application.
Nucleic Acid Aptamers Market Drivers
An Increasing Case Load of Bacterial-Resistant Diseases
Has Propelled the Market Usage of Nucleic Acid Aptamers.
Aptamers, other than recognized forms of treatment, are
highly regarded as antimicrobial agents. Further, biofilm-forming
bacteria, which result in chronic infections, have developed increased
resistance against antibiotic treatments and host defense systems. As per CDC,
in 2019 around 2.8 million anti-microbial resistance infections took place in
the U.S. while claiming nearly 35,000 lives. The technology is highly regarded
in fatal infections due to the presence of anti-biofilm activity.
For More Queries About "Nucleic Acid Aptamers Market" @ https://www.industryarc.com/support.php?id=17454
Peculiar Advantages of Aptamers Over Antibodies Preside
to An Increasing Use of The Former In Multiple Applications.
Antibodies have presented a strong challenge for
targeting small molecules, however, aptamers have conducted effectivity in
targeting small molecules. Owing to this they can bind to small molecules and
dyes and thus be easily used in conventional diagnostic kits, extending their
use to point-of-care diagnostics. Furthermore, aptamers are successful to
bind with larger molecules as well. Nearly 98% of all the molecules tend to be
proteins, which intrinsically are larger than the rest.
Product Launch and Collaboration
In September 2022, Cage Bio - A biotech company, and TAGCyx Biotechnology Company announced the execution of a license-based agreement for the development of TAGX-0003. TAGX-0003 is is a DNA aptamer possessing potent interferon-gamma (IFNg) antagonistic activity developed by TAGCyx.
In June 2022, Waseda
University researchers developed RaptGen, a variational autoencoder that
efficiently discovers new aptamers not included in the input SELEX dataset.
The Major Players in The Market Include
The Major Players in the Nucleic Acid Aptamers Market
include Aptamer Group, Raptamer Discovery Group, Soma-Logic, Aptamer Sciences,
Aptagen, Maravai Lifesciences, Kaneka Corporation, Neo Ventures Biotechnology,
Aptus Biochem, and Base Pair Technologies.
Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers owing to the competitive advantages associated with them. Owing to the following reasons, the nucleic acid aptamers industry will offer lucrative opportunities to marketers.
To request for a quote, provide your details in the below link: https://www.industryarc.com/reports/request-quote?id=17454